The Association Between Azathioprine Genetic Polymorphisms, Clinical Efficacy and Adverse Drug Reactions Among Egyptian Patients with Autoimmune Diseases

被引:1
|
作者
Abuelsoud, Nermeen [1 ,2 ]
Fayed, Hala [3 ]
Elkateeb, Engy [4 ]
机构
[1] British Univ Egypt, Fac Pharm, Dept Clin Pharm Practice, Cairo, Egypt
[2] Egyptian Russian Univ, Fac Pharm, Dept Pharm Practice Clin Pharm, Cairo, Egypt
[3] Cairo Univ, Kasr Alaini Univ Hosp, Fac Med, Dept Rheumatol & Rehabil, Cairo, Egypt
[4] Cairo Univ, Kasr Alaini Univ Hosp, Fac Med, Dept Chem & Clin Pathol, Cairo, Egypt
关键词
azathioprine; genetic polymorphisms; autoimmune diseases; Egyptian patients; THIOPURINE METHYLTRANSFERASE GENOTYPE; IMPLEMENTATION CONSORTIUM GUIDELINES; CROHNS-DISEASE; ALLELES; TPMT; PHARMACOGENETICS; MERCAPTOPURINE; INHERITANCE; PHARMACOLOGY; FREQUENCIES;
D O I
10.2147/PGPM.S285033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The study aimed to detect the frequencies of allelic variants (TPMT*3A, TPMT*3C, and TPMT*3G) in the TPMT genes in the Egyptian population and assess the association between TPMT polymorphisms and azathioprine (AZA)-clinical efficacy and adverse drug reactions among Egyptian patients with autoimmune diseases. Design: A prospective, observational single-center clinical trial. Setting: Rheumatology and Rehabilitation Department, Kasr Alainy University Hospital, Faculty of Medicine, Cairo University. Patients: Patients attending Kasr Alainy Rheumatology Outpatient Clinic between December 1, 2017 and June 30, 2019 were included in the study after signing a consent form. TPMT genetic polymorphisms were detected for all patients, and the association between polymorphisms presence and azathioprine's clinical efficacy and adverse drug reactions were determined. Results: A total of 150 patients with a mean age of 35.85 years were enrolled in this study. About 72% of patients were heterozygous in the TPMT*3 G460A and TPMT*3 A719G mutant alleles and 81% were wild type in the TPMT*2 G238C mutant allele. Abnormal liver function tests were detected in 42% of patients. Myelosuppression was presented as anemia which was detected in 63% of patients, leucopenia in 51%, and thrombocytopenia in 25% of patients. AZA clinical failure has occurred in 50% of patients where AZA was discontinued or shifted to another drug which occurred in 45% of patients. Myelosuppression rates were higher in homozygous patients in the three mutant alleles, but statistically significant in TPMT*2 G238C while not statistically significant in TPMT*3 G460A and TPMT*3 A719G. Females had a higher risk of immunosuppression than males (p-value 0.031). Conclusion: The study provided an overview of the genomic variations in the Egyptian population. Routine TPMT genotyping prior to the initiation of AZA therapy should be considered.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 50 条
  • [31] Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study
    Yang, Jing
    Sun, Ying-zi
    Li, Qun-fang
    Fu, Zheng
    Guan, Yu-yao
    Song, Chao
    Zheng, Lei
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [32] Association between inosine triphosphate pyrophosphohydrolase deficiency and azathioprine-related adverse drug reactions in the Chinese kidney transplant recipients
    Xiong, Hui
    Xin, Hua-Wen
    Wu, Xiao-Chun
    Li, Qing
    Xiong, Lei
    Yu, Ai-Rong
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (03) : 393 - 400
  • [33] Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case–control study
    Jing Yang
    Ying-zi Sun
    Qun-fang Li
    Zheng Fu
    Yu-yao Guan
    Chao Song
    Lei Zheng
    BMC Pharmacology and Toxicology, 24
  • [34] Drug Related Genetic Polymorphisms Affecting Adverse Reactions to Methotrexate, Vinblastine, Doxorubicin and Cisplatin in Patients With Urothelial Cancer
    Tsuchiya, Norihiko
    Inoue, Takamitsu
    Narita, Shintaro
    Kumazawa, Teruaki
    Saito, Mitsuru
    Obara, Takashi
    Tsuruta, Hiroshi
    Horikawa, Yohei
    Yuasa, Takeshi
    Satoh, Shigeru
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2008, 180 (06): : 2389 - 2395
  • [35] Pharmacodynamic and pharmacokinetic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-related psychosis
    Zastrozhin, M.
    EUROPEAN PSYCHIATRY, 2018, 48 : S201 - S202
  • [36] Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions
    Hsu, Hung-Chih
    Chung, Wen-Hung
    Lin, Yung-Chang
    Yang, Tsai-Sheng
    Chang, John Wen-Cheng
    Hsieh, Chia-Hsun
    Hung, Shuen-Iu
    Lu, Chun-Wei
    Chen, Jen-Shi
    Chou, Wen-Chi
    Wang, Chuang-Wei
    ALLERGOLOGY INTERNATIONAL, 2024, 73 (04) : 580 - 586
  • [37] Association between functional SIRT1 polymorphisms and the clinical characteristics of patients with autoimmune thyroid disease
    Sarumaru, Mika
    Watanabe, Mikio
    Inoue, Naoya
    Hisamoto, Yuko
    Morita, Emi
    Arakawa, Yuya
    Hidaka, Yoh
    Iwatani, Yoshinori
    AUTOIMMUNITY, 2016, 49 (05) : 329 - 337
  • [38] Association between Polymorphisms of IL-23/IL-17 Pathway and Clinical Phenotypes of Autoimmune Thyroid Diseases
    Cai, Tiantian
    Wang, Guofei
    Yang, Yanping
    Mu, Kaida
    Zhang, Jing
    Jiang, Yanfei
    Zhang, Jin-an
    IRANIAN JOURNAL OF IMMUNOLOGY, 2022, 19 (02) : 139 - 149
  • [39] Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia
    Ferrari, Marco
    Bolla, Emilio
    Bortolaso, Paola
    Callegari, Camilla
    Poloni, Nicola
    Lecchini, Sergio
    Vender, Simone
    Marino, Franca
    Cosentino, Marco
    PSYCHIATRY RESEARCH, 2012, 200 (2-3) : 1014 - 1017
  • [40] Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors
    Zhang, Qiang
    Xu, Jianghao
    Qian, Yi
    Chen, Liang
    Li, Qingya
    Xu, Kangjing
    Chen, Ming
    Sun, Luning
    He, Zhongyuan
    Yang, Li
    Zhang, Diancai
    Wang, Linjun
    Sun, Xiaofeng
    Wang, Yongqing
    Xu, Hao
    Xu, Zekuan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (12) : 2780 - 2787